logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Protocol

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial

Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M,  et al.
2023-11-30 • Trials
2023-11-30 • Trials
BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...
Journal Article
|
Commentary

Introducing new and repurposed TB drugs: the endTB experience

Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...
Journal Article
|
Protocol

Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial

Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E,  et al.
2021-09-25 • Trials
2021-09-25 • Trials
BACKGROUND
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...